CYSTADENOCARCINOMA OVARY

This adverse event was reported 6 times

CYSTADENOCARCINOMA OVARY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 TESTOSTERONE UNDECANOATE 1 0.0005
1 CANAKINUMAB 1 0.0001
2 CETIRIZINE HYDROCHLORIDE TABLETS 1 0.0000
3 OCRELIZUMAB 1 0.0000
4 APIXABAN 1 0.0000
5 OMALIZUMAB 1 0.0000
6 TACROLIMUS OINTMENT 0.1% 1 0.0000
7 TACROLIMUS EXTENDED-RELEASE CAPSULES 1 0.0000
8 TACROLIMUS 1 0.0000
9 SECUKINUMAB 1 0.0000
See all drugs enriched for association with CYSTADENOCARCINOMA OVARY

CYSTADENOCARCINOMA OVARY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Interleukin-17A Antagonist [EPC] 1 0.0000
1 Anti-IgE [EPC] 1 0.0000
2 Factor Xa Inhibitor [EPC] 1 0.0000
3 Progestin [EPC] 1 0.0000
4 CD20-directed Cytolytic Antibody [EPC] 1 0.0000
5 Corticosteroid [EPC] 1 0.0000
See all drug classes enriched for association with CYSTADENOCARCINOMA OVARY